The aim of treatment is to slow down the deterioration of renal function and prevent organ complications.
Patients belonging to risk groups for kidney disease (patients with diabetes or cardiovascular disease, hypertension, obesity or family history of kidney disease) should be screened (plasma creatinine and chemical urinalysis and/or urine albumin/creatinine ratio).
The metabolic sequelae of renal failure and the risk factors for atherosclerosis should be identified and treated. The risk of cardiovascular disease increases as soon as there is proteinuria even if renal function is still normal.
The number of patients with renal failure is increasing, particularly because type 2 diabetes is becoming more common and the population is ageing.
It is important to start treatment as soon as possible.
In an elderly person, eGFR may be decreased merely because of advanced age even though the plasma creatinine concentration is still completely normal. As a solitary finding, this is not a sign of renal disease.
Renal ultrasonography is indicated if a problem in urine flow is suspected or if renal failure has suddenly progressed without a clear reason.
If renal ultrasonography has never been done or not been done for several years, it should be done anyway.
As part of the diagnostic workup, the level of proteinuria Proteinuria should be examined by determining the urine albumin/creatinine ratio (or 24-hour urinary protein excretion) and any haematuria should be identified (chemical urinalysis) and its extent determined by particle counting.
The magnitude of proteinuria should be monitored. A high level of proteinuria is an independent risk factor for aggravation of renal failure.
Haematuria is usually not an independent risk factor for aggravation of renal failure, but, if it is increasing, it is usually a sign of activation of renal disease (e.g. in vasculitis)
As renal failure remains asymptomatic for a long time, monitoring of plasma creatinine and chemical screening of urine and/or measurement of urine albumin/creatinine ratio should be performed particularly in risk groups.
Disease-specific calculators to predict the progression of renal failure are available (e.g. for type 2 diabetes, IgA glomerulonephritis), although the use of all of these in clinical practice is not yet established.
Chronic renal disease is defined as renal damage (any abnormal renal finding; most commonly either an abnormal finding in a urine test and/or impaired renal filtration< 60 ml/min/1.73m2 ) that has lasted for at least 3 months.
In an elderly person, eGFR may be decreased merely because of advanced age even though the plasma creatinine concentration is still completely normal. As a solitary finding, this is not a sign of renal disease.
If urine analysis is normal and the plasma creatinine concentration is still increased on repeat testing, determining plasma cystatine C concentration may provide additional information on whether the patient has renal failure or not Increased Blood Creatinine Concentration, Egfr and Renal Function Tests.
Therapeutic interventions to slow the progression of renal disease
Treatment of hypertension
The target blood pressure level has become stricter for patients who are not undergoing dialysis or have not received a renal transplant. The aim of this is to reduce cardiovascular mortality and morbidity, not just nephroprotection. However, not all guidelines call for such strict target levels.
Systolic blood pressure < 120 mmHg
The diastolic blood pressure target has not been separately defined but an appropriate target of < 80 mmHg can probably be reached if systolic blood pressure is at the target level.
For organ transplant recipients, the target blood pressure level is < 130/80 mmHg.
If the strict target cannot be reached due to adverse effects, a higher level is considered acceptable http://pubmed.ncbi.nlm.nih.gov/33637192/, particularly in elderly patients and patients with multiple diseases as well as those with symptomatic postural hypotension.
Prior to treatment and 1-3 weeks after the start of treatment, check plasma creatinine and potassium.
Start with a low dose, and increase the dose carefully if there is already more than mild renal failure. Medication can also be used for patients undergoing dialysis unless hyperkalaemia is a problem.
At the beginning of the therapy a slight increase in the creatinine concentration (< 20-30% of baseline) is sometimes detected. This does not prevent continuing therapy; however, follow-up is necessary. If a greater increase is seen, constriction of the renal arteries should be suspected. An acceptable increase in plasma potassium concentration is up to the level of 5.5 mmol/l but measures to lower the concentration should be started as soon as the reference range is exceeded (see section on hyperkalaemia).
If the patient has gastroenteritis or some other cause of fluid loss, he/she should be advised to temporarily discontinue taking drugs inhibiting the RAA system (risk of hyperkalaemia and aggravation of renal failure), but as soon as the acute situation becomes normalized, and after checking the plasma potassium and creatinine concentrations, the medication should be resumed.
Similar lifestyle changes are recommended as for the general population, particularly restricting sodium intake to < 2 g/24 h and regular physical exercise.
The combination of ACE inhibitors and ARBs is no longer recommended as this carries a risk of hyperkalaemia and significant aggravation of renal failure.
The HbA1c target level varies individually, being < 47-64 mmol/mol (< 6.5-8%) before the dialysis stage.
Of antidiabetic drugs, SGLT-2 inhibitors and GLP-1 analogues additionally decreasing proteinuria and/or slowing down eGFR reduction are particularly useful.
Avoidance of nephrotoxic agents (e.g. NSAIDs, CT contrast media). Check, if available, electronic database(s) for the usability of drugs in different levels of renal function.
The general intake target for patients with diabetes before the dialysis stage is similar to the WHO recommendations (0.8 g/kg ideal weight/24 h).
Keeping the dietary protein intake at a moderate level of 0.8-1.0 g/kg ideal weight/24 h is also recommended for other patients with renal failure Protein Restriction for Diabetic Kidney Disease; at the dialysis stage, the need for dietary protein will increase.
Phosphate restriction usually involves partial protein restriction. A daily protein intake exceeding 1.3 g/kg is not recommended if there is a risk of progressive renal failure.
Protein restriction probably has no benefit in patients with an eGFR ≥ 60 ml/min.
A varied diet rich in vegetables may prevent renal failure and slow down its progression.
Avoidance of obesity
Metabolic acidosis caused by renal failure may also be a risk factor for progression of renal failure, and its treatment is also useful from the viewpoint of nephroprotection.
There is no unequivocal evidence that medication lowering serum urate levels slows down the progression of renal failure.
There is currently no evidence of benefits in all patient groups (organ transplant recipients, patients with polycystic kidney disease, vasculitis, lupus).
Medication is useful regardless of diabetes control or other antidiabetic medication.
Empagliflozin also prevents eGFR reduction in patients with hardly any proteinuria, regardless of whether they have diabetes.
Starting such medication is not currently recommended if eGFR is < 20 ml/min/1.73 m2 , but medication already started can probably be continued until the beginning of the dialysis stage.
At least patients (according to trial inclusion criteria) with eGFR 20-45 (even without proteinuria) or eGFR 45-90 and urine albumin/creatinine ratio 22.6 mg/mmol or more at the start of medication will benefit of it.
Dabagliflozin slows down the progression of renal failure and reduces proteinuria in patients with and without diabetes.
Starting such medication is not currently recommended if eGFR is < 25 ml/min/1.73 m2 , but medication already started can probably be continued until the beginning of the dialysis stage.
At least patients (according to trial inclusion criteria) with eGFR 25-75 and urine albumin/creatinine ratio 22.6-565 mg/mmol at the start of medication will benefit of it.
Dabagliflozin and empagliflozin are so far the only SLGT-2 inhibitors indicated for the treatment of chronic kidney disease.
Starting treatment with any SGLT-2 inhibitor is associated with an acutely reduced glomerular filtration rate (GFR). The amount of reduction is to some extent proportional to the long-term efficacy of the medication and should not lead to pausing the medication in the absence of other reasons.
About 1 month after starting the medication, check eGFR, particularly if the patient has a history of episodes of acute renal failure, if the glomerular filtration rate was significantly reduced at the beginning of medication or if there is reason to suspect problems related to dehydration.
Steroidal mineralocorticoid receptor blockers (spironolactone, eplerenone) lower blood pressure and reduce proteinuria and may stabilize renal function regardless of the diabetes status, but they increase the risk of hyperkalaemia if combined with ACE inhibitors or ARBs.
Of non-steroidal mineralocorticoid receptor blockers, finerenone has been studied the most. Combined with ACE inhibitors or ARBs, it reduces proteinuria and slows down the progression of renal failure in people with diabetes. It is indicated in the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes.
ACE inhibitors, ARBs and mineralocorticoid receptor blockers must be reduced if hyperkalaemia cannot otherwise be controlled.
An acceptable increase in plasma potassium concentration is up to the level of 5.5 mmol/l but measures to lower the concentration should be started as soon as the reference range is exceeded.
Oedema can be managed by restricting sodium intake, by suppressing proteinuria and by loop diuretics. Fluid restriction may be needed in difficult cases.
Metabolic acidosis
The acid excretion ability of the kidneys starts to decrease clearly when eGFR falls to 30-45 ml/min.
Medication should be started when the bicarbonate level in the serum acid-base balance falls to below 22 mmol/. The usual target is the normal range.
Metabolic acidosis can be corrected by calcium carbonate tablets otherwise used for phosphate restriction and, additionally, by sodium bicarbonate tablets, as necessary. The dosage is individual.
Renal erythropoietin production decreases in patients with renal failure.
Normochromic and normocytic anaemia can be considered renal if other causes of anaemia have been excluded and eGFR has decreased to a level where renal anaemia commonly occurs. . Measurement of blood erythropoietin levels is not useful.
Anaemia develops gradually, and commonly occurs at eGFR levels of about 30 ml/min. In people with diabetes, particularly, it may occur at eGFR levels of 40-45 ml/min., already.
Reduced urinary phosphate excretion causes secondary hyperparathyroidism, which can be observed at an eGFR < 60 ml/min., already.
Serum parathyroid hormone (PTH) concentration increases early, blood calcium and phosphate concentrations only later (calcium decreasing, phosphate increasing).
Reduction of dietary phosphate intake and phosphate binding medication should only be started when the blood phosphate level exceeds the reference range. The main focus should be on the trends of repeated measurements and on their combined assessment.
Restriction of dietary phosphate intake (dairy products and wholemeal products) is of primary importance; a clinical dietitian can provide instructions.
The number of calcium tablets should be kept reasonable; usually calcium doses exceeding 1.5 g/day are not recommended without a special reason (correction of hypocalcaemia, for example).
Vitamin D2 or D3 should be given to all patients, unless the dietary intake appears to be certainly sufficient. Measure 25-OH vitamin D levels, as necessary.
The aim is to keep blood calcium and phosphate levels within the reference ranges and PTH approximately at a level close to but not exceeding the upper limit of the reference range, although the optimal PTH level prior to dialysis stage is unclear. At the dialysis stage, target phosphate and PTH levels are higher. Hypercalcaemia should be avoided at every stage.
Screening for renal failure in high-risk patients (patients with diabetes, hypertension or cardiovascular disease or family history of kidney disease) and its detection
Detection, treatment and follow-up of factors affecting renal failure (blood pressure, diabetes, proteinuria, other factors, see here).
Diet therapy (clinical dietitian): phosphate restriction, restriction of salt intake and, as necessary, restriction of potassium and protein intake
Follow-up and management of mild and moderate renal failure
Check-ups every 6-12 months for patients with an eGFR of 60-89 ml/min.
Check-ups every 4-6 months for patients with an eGFR of 30-59 ml/min.
Basic blood count with platelet count, creatinine, eGFR, potassium, sodium, urea, ionized calcium, inorganic phophate, parathyroid hormone (if possible), albumin, urinary albumin/creatinine ratio or 24-hour urinary protein excretion, chemical screening of urine, blood gas analysis (if possible), HbA1c (in patients with diabetes) and lipids (once a year plasma cholesterol, fasting plasma triglycerides, fasting plasma HDL cholesterol, plasma LDL cholesterol).
Renal ultrasonography if a problem with urinary flow is suspected or if renal function has suddenly reduced without a clear reason.
Specialized care
More specific diagnosis of the renal disease, especially when renal biopsy is needed
Difficulties in the management of blood pressure or oedema
Initiation of erythropoietin therapy, HIF-PH inhibitor (roxadustat) or intravenous iron therapy
Treatment of secondary hyperparathyroidism: initiation of treatment with calcium-free phosphate binders or alfacalcidol/paricalcitol/calcimimetic and consideration of operative treatment
Significant increase in proteinuria despite optimal treatment of blood pressure and proteinuria (urinary protein excretion > 3 g/24 h)
Rapid deterioration of renal function with no obvious reason
Assessment for active intervention when eGFR is less than about 20 ml/min (some other level, such as < 30 ml/min., may have been agreed locally): will the patient benefit from possible initiation of dialysis treatment or organ transplant as the renal disease progresses?
References
Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400(10365):1788-1801. [PubMed]
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102(5S):S1-S127. [PubMed]
Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43(6):474-484. [PubMed]
Drawz PE, Beddhu S, Bignall ONR 2nd et al. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD. Am J Kidney Dis 2022;79(3):311-327. [PubMed]
de Boer IH, Khunti K, Sadusky T et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2022;102(5):974-989. [PubMed]
Locatelli F, Del Vecchio L. Hypoxia-Inducible Factor-Prolyl Hydroxyl Domain Inhibitors: From Theoretical Superiority to Clinical Noninferiority Compared with Current ESAs? J Am Soc Nephrol 2022;33(11):1966-1979. [PubMed]
Rossing P, Caramori ML, Chan JCN et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022;102(5):990-999. [PubMed]
The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023;388(2):117-127. [PubMed]
Yau K, Dharia A, Alrowiyti I et al. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep 2022;7(7):1463-1476. [PubMed]
Lyu B, Singh T, Astor B: Epidemiology and outcomes for the chronic kidney disease, NephSap, vol 21, no 2, 2022, 121-134.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021;99(3S):S1-S87. [PubMed]
Agarwal R, Kolkhof P, Bakris G et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021;42(2):152-161. [PubMed]
Heerspink HJL, Cherney DZI. Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. Clin J Am Soc Nephrol 2021;16(8):1278-1280. [PubMed]
Chung EY, Ruospo M, Natale P et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2020;10(10):CD007004. [PubMed]
Carrero JJ, González-Ortiz A, Avesani CM et al. Plant-based diets to manage the risks and complications of chronic kidney disease. Nat Rev Nephrol 2020;16(9):525-542. [PubMed]
de Boer IH, Caramori ML, Chan JCN et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020;98(4):839-848. [PubMed]
Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol 2021;43(5):717-728. [PubMed]
Wesson DE, Buysse JM, Bushinsky DA. Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease. J Am Soc Nephrol 2020;31(3):469-482. [PubMed]
Ketteler M, Block GA, Evenepoel P et al. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. Ann Intern Med 2018;168(6):422-430. [PubMed]
Sun LJ, Sun YN, Shan JP et al. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. J Diabetes Investig 2017;8(4):609-618. [PubMed]
Cheung AK, Rahman M, Reboussin DM et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol 2017;28(9):2812-2823. [PubMed]
Currie G, Taylor AH, Fujita T et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 2016;17(1):127. [PubMed]
Andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int 2013;84(3):622-3. [PubMed]
Chapter 3: Management of progression and complications of CKD. Kidney Int Suppl (2011) 2013;3(1):73-90. [PubMed]
Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157(4):251-62. [PubMed]
Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144(1):21-8. [PubMed]
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 Suppl 1):S1-290. [PubMed]
Klahr S, Levey AS, Beck GJ ym. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330(13):877-84. [PubMed]
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86. [PubMed]